Comparative Clinical and Economic Outcomes among Venous Thromboembolism Patients who Initiated Apixaban or Warfarin in the United States Medicare Population (VTE CER in Medicare)

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS24902
• Study ID:
  35610
• Official title and acronym:
  Comparative Clinical and Economic Outcomes among Venous Thromboembolism Patients who Initiated Apixaban or Warfarin in the United States Medicare Population (VTE CER in Medicare)
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This study will evaluate the patient profiles, current antithrombotic patterns, and real-world clinical & economic outcomes among patients with VTE
• Study status:
  Finalised

Study timelines

Date when funding contract was signed

Actual:11/09/2017

Study start date

Planned:01/08/2018

Actual:08/01/2018

Date of final study report

Planned:02/06/2020

Actual:02/06/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable